Protein
and cell interactions on implanted, blood-contacting medical
device surfaces can lead to adverse biological reactions. Medical-grade
poly(vinyl chloride) (PVC) materials have been used for decades, particularly
as blood-contacting tubes and containers. However, there are numerous
concerns with their performance including platelet activation, complement
activation, and thrombin generation and also leaching of plasticizers,
particularly in clinical applications. Here, we report a surface modification
method that can dramatically prevent blood protein adsorption, human
platelet activation, and complement activation on commercial medical-grade
PVC materials under various test conditions. The surface modification
can be accomplished through simple dip-coating followed by light illumination
utilizing biocompatible polymers comprising zwitterionic carboxybetaine
(CB) moieties and photosensitive cross-linking moieties. This surface
treatment can be manufactured routinely at small or large scales and
can impart to commercial PVC materials superhydrophilicity and nonfouling
capability. Furthermore, the polymer effectively prevented leaching
of plasticizers out from commercial medical-grade PVC materials. This
coating technique is readily applicable to many other polymers and
medical devices requiring surfaces that will enhance performance in
clinical settings.